183 related articles for article (PubMed ID: 36397023)
1. A case of ischemic stroke with hemorrhagic transformation associated with essential thrombocythemia and JAK-2 V617F mutation.
Yan R; Mi D; Qiu X; Li Z
BMC Neurol; 2022 Nov; 22(1):437. PubMed ID: 36397023
[TBL] [Abstract][Full Text] [Related]
2. Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report.
Xie J; Geng L; Yuan B; Guo Y; Zhang Z
BMC Neurol; 2020 Nov; 20(1):407. PubMed ID: 33158429
[TBL] [Abstract][Full Text] [Related]
3. Specific mechanisms of subarachnoid hemorrhage accompanied by ischemic stroke in essential thrombocythemia: two case reports and a literature review.
Sugiyama M; Ueno Y; Kamo H; Edahiro Y; Miyamoto N; Yamashiro K; Tanaka R; Shimo Y; Komatsu N; Hattori N
J Neurol; 2019 Aug; 266(8):1869-1878. PubMed ID: 31049728
[TBL] [Abstract][Full Text] [Related]
4. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
5. An unusual cause of cerebellar hemorrhage in a young patient: essential thrombocythemia.
Adam R; Priglinger M; Harrington T; Gottlieb D; Krause M
J Stroke Cerebrovasc Dis; 2014; 23(5):e373-4. PubMed ID: 24582788
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
7. Late In-Stent Thrombosis After Carotid Artery Stenting for Symptomatic Internal Carotid Artery Stenosis in a Patient With JAK2 V617F-Positive Essential Thrombocythemia: An Illustrative Case Report.
Arai M; Nakase K; Nishimura F; Nakagawa I; Nakase H
Cureus; 2023 Oct; 15(10):e47688. PubMed ID: 38021556
[TBL] [Abstract][Full Text] [Related]
8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
9. Essential Thrombocythemia and Ischemic Stroke: A Case Series of Five
Kim BK; Eah KY; Park JM
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512112
[No Abstract] [Full Text] [Related]
10. Essential thrombocythemia - a predisponent factor for stroke.
Batista TFP; Manuel PF; Correia AC
Rev Assoc Med Bras (1992); 2019 Jul; 65(6):772-774. PubMed ID: 31340302
[TBL] [Abstract][Full Text] [Related]
11. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
12. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
13. Acute ST-segment elevation myocardial infarction: a rare initial presentation of previously undiagnosed essential thrombocythemia.
Singla A; Jagasia D; Garg M; Lowry PA; Stapleton D
Platelets; 2012; 23(6):463-6. PubMed ID: 22686448
[TBL] [Abstract][Full Text] [Related]
14. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.
Falanga A; Marchetti M; Vignoli A; Balducci D; Russo L; Guerini V; Barbui T
Exp Hematol; 2007 May; 35(5):702-11. PubMed ID: 17577920
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
[TBL] [Abstract][Full Text] [Related]
16. Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Gadisseur A; Lam KH; De Raeve H; Schroyens W
Acta Haematol; 2015; 133(1):56-63. PubMed ID: 25116182
[TBL] [Abstract][Full Text] [Related]
17. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
18. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2
Saki N; Shirzad R; Rahim F; Saki Malehi A
Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126
[TBL] [Abstract][Full Text] [Related]
19. Progression of coronary calcium burden and carotid stiffness in patients with essential thrombocythemia associated with JAK2 V617F mutation.
Anžič Drofenik A; Vrtovec M; Božič Mijovski M; Sever M; Preložnik Zupan I; Kejžar N; Blinc A
Atherosclerosis; 2020 Mar; 296():25-31. PubMed ID: 32005002
[TBL] [Abstract][Full Text] [Related]
20. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
